Gene expression microarray technologies in the development of new therapeutic agents

European Journal of Cancer

Volumn 40, Issue 17 SPEC. ISS., 2004, Pages 2560-2591

  Clarke, Paul A ^a   Poele, Robert Te ^a   Workman, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Cancer; Drug development; Microarray; Pharmacology

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (4 AMINO 3 METHYLPHENYL)BENZOTHIAZOLE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AMITROLE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CCT 018159; CISPLATIN; CYCLOSPORIN A; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; FLAVOPIRIDOL; FOTEMUSTINE; GEFITINIB; IMATINIB; INDISULAM; MESSENGER RNA; MS 27275; PACLITAXEL; RALTITREXED; RNA; ROSCOVITINE; STAUROSPORINE; TACROLIMUS; TRABECTEDIN; TRASTUZUMAB; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GENETICS; CANCER MODEL; CANCER PATIENT; CANCER THERAPY; CARCINOGENESIS; CHEMICAL ANALYSIS; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DNA MICROARRAY; DRUG ACTIVITY; DRUG APPROVAL; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TARGETING; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE SEQUENCE; GENE STRUCTURE; GENETIC ANALYSIS; GENETIC PROCEDURES; GENOME ANALYSIS; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; HUMAN GENOME; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT GENE; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOLECULAR BIOLOGY; NONHUMAN; OUTCOMES RESEARCH; OVARY CANCER; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; RNA INTERFERENCE; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS; TECHNOLOGY; TISSUE CULTURE;

EID: 8444220472     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.07.024     Document Type: Article

References (160)

1. E.S. Lander, R.M. Linton, and B. Birrer Initial sequencing and analysis of the human genome Nature 409 2001 860 921
2. J.C. Venter, M.D. Adams, and E.W. Myers The sequence of the human genome Science 291 2001 1304 1351
3. J.D. Watson, and F.H. Crick Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid Nature 171 1953 737 738
4. J. Grimwood, and J. Schmutz Genomics: six is seventh Nature 425 2003 775
5. P. Workman Overview: changing times: developing cancer drugs in genomeland Curr Opin Investig Drugs 2 2001 1128 1135
6. M. van Duin, H. Woolson, D. Mallinson, and D. Black Genomics in target and drug discovery Biochem Soc Trans 31 2003 429 432
7. P. Workman, and S.B. Kaye Translating basic research into new cancer therapeutics Trends Mol Med 8 2001 S1 9
8. M. Jain, C. Arvanitis, and K. Chu Sustained loss of a neoplastic phenotype by brief inactivation of MYC Science 297 2002 102 104
9. L. Chin, A. Tam, and J. Pomerantz Essential role for oncogenic Ras in tumour maintenance Nature 400 1999 468 472
10. I.B. Weinstein Cancer. Addiction to oncogenes-the Achilles heal of cancer Science 297 2002 63 64
11. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
12. J. Baselga, and S.D. Averbuch ZD1839 ('Iressa') (1,2) as an anticancer agent Drugs 60 2000 33 40
13. D. Slamon, and M. Pegram Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials Semin Oncol 28 2001 13 19
14. B.J. Druker STI571 (Gleevec) as a paradigm for cancer therapy Trends Mol Med 8 2002 S14 18
15. D.J. Duggan, M. Bittner, Y. Chen, P. Meltzer, and J.M. Trent Expression profiling using cDNA microarrays Nat Gen 21 1999 10 14
16. P. Heyde, R. Qi, and K. Abernathy A concise guide to microaray analysis Biotechniques 29 2000 548 562
17. The chipping forecast. Nat Gen 1999; (Suppl. 21):1-160
18. The chipping forecast II. Nat Gen 2002; (Suppl. 32):461-552
19. M.B. Eisen, and P.O. Brown DNA arrays for analysis of gene expression Methods Enzymol 303 1999 179 205
20. D.J. Lockhart, and E.A. Winzeler Genomics, gene expression and DNA arrays Nature 405 2000 827 836
21. J. Quackenbush Microarray data normalisation and transformation Nat Gen Suppl. 32 2002 496 501
22. W.S. Cleveland Robust locally weighted regression and smoothing scatterplots J Am Stat Assoc 74 1979 829 836
23. P. Baldi, and A.D. Long A Bayesian framework for the analysis of microarray expression data: regularized t-test and statistical inferences of gene changes Bioinformatics 17 2001 509 519
24. M. Bittner, P. Meltzer, and J. Trent Data analysis and integration: of steps and arrows Nat Gen 22 1999 213 215
25. R.A. Young Biomedical discovery with DNA arrays Cell 102 2000 9 15
26. D.E. Bassett, M.B. Eisen, and M.S. Boguski Gene expression informatics - it's all in your mine Nat Gen Suppl. 21 1999 51 55
27. O. Ermolaeva, M. Rastogi, and K.D. Pruitt Data management and analysis for gene arrays Nat Gen 20 1998 19 23
28. M.B. Eisen, P.T. Spellman, P.O. Brown, and D. Botstein Cluster analysis and display of genome-wide expression patterns Proc Natl Acad Sci USA 95 1998 14863 14868
29. P. Tamayo, D. Slonim, and J. Mesirov Interpretting the patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation Proc Natl Acad Sci USA 96 1999 2907 2912
30. T.R. Golub, D.K. Slonim, and P. Tamayo Molecular classification of cancer: class discovery and class prediction by gene expression monitoring Science 286 1999 531 537
31. V.G. Tusher, R. Tibshirani, and G. Chu Significance analysis of microarrays applied to the ionizing radiation response Proc Natl Acad Sci USA 98 2001 5116 5121
32. J. Khan, J.S. Wei, and M. Ringner Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks Nat Med 7 2001 673 679
33. P. Workman New drug targets for genomic cancer therapy: successes, limitations, opportunities and future challenges. Curr Cancer Drug Targets 1 2001 33 47
34. A. Balmain, J. Gray, and B. Ponder The genetics and genomics of cancer Nat Gen 33 2003 238 244
35. Z. Szallasi Gene expression patterns and cancer Nat Biotech 16 1998 1292 1293
36. E.J. Yeoh, M.E. Ross, and S.A. Shurtleff Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling Cancer Cell 1 2002 133 143
37. S.A. Armstrong, J.E. Staunton, and L.B. Silverman MLL translocations specify a distinct gene expression profile that distinguishes a unique leukaemia Nat Gen 30 2002 41 47
38. R.W. Stam, M.L. den Boer, and J.P.P. Meijerink Differential mRNA expression of Ara-C-metabolising enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia Blood 101 2003 1270 1276
39. A.A. Ferrando, D.S. Neuberg, and J. Staunton Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia Cancer Cell 1 2002 75 87
40. A.A. Alizadeh, M.B. Eisen, and R.E. Davis Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 403 2000 503 511
41. A. Rosenwald, G. Wright, and W.C. Chan The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma New Engl J Med 346 2002 1937 1947
42. R.E. Davis, K.D. Brown, U. Siebenlist, and L.M. Staudt Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells J Exp Med 194 2001 1861 1874
43. M.A. Shipp, K.N. Ross, and P. Tamayo Diffuse large B-cell lymphoma outcome prediction by gene expression profiling and supervised machine learning Nat Gen 8 2002 68 74
44. A. Lerner, D. Kim, and R. Lee The cAMP signaling pathway as a therapeutic target in lymphoid malignancies Leuk Lymphoma 37 2000 39 51
45. B.A. Teicher, E. Alvarez, L.G. Mendelsohn, G. Ara, K. Menon, and D.K. Ways Enzymatic rationale and preclinical support for a potent protein kinase C beta inhibitor in cancer therapy Adv Enzyme Regul 39 1999 313 327
46. K.S. Elenitoba-Johnson, S.D. Jenson, and R.T. Abbott Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy Proc Natl Acad Sci USA 100 2003 7259 7264
47. C.M. Perou, T. Serlie, and M.B. Eisen Molecular portraits of human breast tumours Nature 406 2000 747 752
48. T. Sorlie, C.M. Perou, and R. Tibshirani Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 2001 10869 10874
49. T. Sorlie, R. Tibshirani, and J. Parker Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 100 2003 8418 8423
50. L.J. van 't Veer, H. Dai, and M.J. van de Vijver Gene expression profiling predicts clinical outcome of breast cancer Nature 415 2002 530 536
51. M.J. van de Vijver, Y.D. He, and L.J. van't Veer A gene-expression signature as a predictor of survival in breast cancer New Engl J Med 347 2002 1999 2009
52. C. Sotiriou, S.-Y. Neo, and L.M. McShane Breast cancer classification and prognosis based on gene expression profiles from a population-based study Proc Natl Acad Sci USA 100 2003 10393 10398
53. S.M. Dhanasekaran, T.R. Barrette, and D. Ghosh Delineation of prognostic biomarkers in prostate cancer Nature 412 2001 822 826
54. J. Luo, D.J. Duggan, and Y. Chen Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling Cancer Res 61 2001 4683 4688
55. J.B. Welsh, L.M. Sapinoso, and A.I. Su Analysis of gene expression identifies candidate markers and pharmalogical targets in prostate cancer Cancer Res 61 2001 5974 5978
56. D. Singh, P.G. Febbo, and K. Ross Gene expression correlates of clinical prostate cancer behavior Cancer Cell 1 2002 203 209
57. D.R. Rhodes, T.R. Barrette, M.A. Rubin, D. Ghosh, and A.M. Chinnaiyan Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer Cancer Res 62 2002 4427 4433
58. E.S. Pizer, B.R. Pflug, G.S. Bova, W.F. Han, M.S. Udan, and J.B. Nelson Increased fatty acid synthase as a therapeutic in androgen-independent prostate cancer progression Prostate 47 2001 102 110
59. M.E. Garber, O.G. Troyanskaya, and K. Schluens Diversity of gene expression in adenocarcinoma of the lung Proc Natl Acad Sci USA 98 2001 13784 13789
60. A. Bhattacharjee, W.G. Richards, and J. Staunton Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses Proc Natl Acad Sci USA 98 2001 13790 13795
61. D.G. Beer, S.L.R. Kardia, and C.-C. Huang Gene-expression profiles predict survival of patients with lung adenocarcinoma Nat Med 8 2002 816 824
62. D.A. Wigle, I. Jurisica, and N. Radulovich Molecular profiling of non-small cell lung cancer and correlation with disease-free survival Cancer Res 62 2002 3005 3008
63. R. Baird, and P. Workman Emerging molecular therapies drugs interfering with signal transduction pathways M. Bronchud M.A. Foote G. Giaccone O. Olopade P. Workman Principles of molecular oncology 2003 Humana Press Inc. Totowa, NJ, USA 569 606
64. J.B. Welsh, P.P. Zarrinker, and L.M. Sapinoso Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer Proc Natl Acad Sci USA 98 2001 1176 1181
65. K. Ono, T. Tanaka, and T. Tsunoda Identification by cDNA microarray of genes involved in ovarian carcinogenesis Cancer Res 60 2000 5007 5011
66. D.A. Notterman, U. Alon, A.J. Sierk, and A.J. Levine Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays Cancer Res 61 2001 3124 3130
67. U. Alon, N. Barkai, and D.A. Notterman Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays Proc Natl Acad Sci USA 96 1999 6745 6750
68. O. Kithara, Y. Furukawa, and T. Tanaka Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia Cancer Res 61 2001 3544 3549
69. T.-T. Zou, F.M. Selaru, and Y. Xu Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon Oncogene 21 2002 4855 4862
70. Y.-M. Lin, Y. Furukawa, T. Tsunoda, C.-T. Yue, K.-C. Yang, and Y. Nakamura Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas Oncogene 21 2002 4120 4128
71. P.A. Clarke, M.L. George, and S. Easdale Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profiling Cancer Res 63 2003 6855 6863
72. K. Birkenkamp-Demtroder, L.L. Christensen, and S.H. Olesen Gene expression in colorectal cancer Cancer Res 62 2002 4352 4363
73. C. Kihara, T. Tsunoda, and T. Tanaka Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles Cancer Res 61 2001 6474 6479
74. M. Bittner, P. Meltzer, and Y. Chen Molecular classification of cutanteous malignant melanoma by gene expression profiling Nature 406 2000 536 540
75. K.M. Carr, M. Bittner, and J.M. Trent Gene-expression profiling in human cutaneous melanoma Oncogene 22 2003 3076 3080
76. A.T. Weeraratna, Y. Jiang, and G. Hostetter Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma Cancer Cell 1 2002 279 288
77. E.A. Clark, T.R. Golub, E.S. Lander, and R.O. Hynes Genomic analysis of metastasis reveals an essential role for RhoC Nature 406 2000 532 535
78. E. Sahai, and C.J. Marshall RHO-GTPases and cancer Nat Rev Cancer 2 2002 133 142
79. J.Y. Ljubimova, A.J. Lakhter, and A. Loksh Overexpression of a4 chain-containing laminins in human glial tumors identified by gene microarray analysis Cancer Res 61 2001 5601 5610
80. D.S. Rickman, M.P. Bobek, and D.E. Misek Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis Cancer Res 61 2001 6885 6891
81. S.L. Pomeroy, P. Tamayo, and M. Gaasenbeek Prediction of central nervous system embryonal tumour outcome based on gene expression Nature 415 2002 436 442
82. T.J. MacDonald, K.M. Brown, and B. LaFleur Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease Nat Gen 29 2001 143 152
83. M. Branca Putting gene arrays to the test Science 300 2003 238
84. K. Ellwood-Yen, T.G. Graeber, and J. Wongvipat Myc-driven murine prostate cancer shares molecular features with human prostate tumors Cancer Cell 4 2003 223 238
85. C.D. Chen, D.S. Welsbie, and C. Tran Molecular determinants of resistance to antiandrogen therapy Nat Med 10 2004 33 39
86. Y. Kang, P.M. Siegel, and W. Shu A multigenic program mediating breast cancer metastasis to bone Cancer Cell 3 2003 537 549
87. J. Lamb, S. Ramaswarmy, and H.L. Ford A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer Cell 114 2003 3230 3340
88. R. Vernell, K. Helin, and H. Muller Identification of target genes of the p16INK4A-pRb-E2F pathway J Biol Chem 278 2003 46124 46137
89. H. Muller, A.P. Bracken, and R. Vernell E2Fs regulate the expression of genes involved in differention, development proliferation, and apoptosis Genes Dev 15 2001 267 285
90. V.R. Iyer, M.B. Eisen, and D.T. Ross The transcriptional program in the response of human fibroblasts to serum Science 283 1999 83 87
91. D. Fambrough, K. McClure, A. Kazlauskas, and E.S. Lander Diverse signaling pathways activated by growth factor receptors induce broadly overlapping, rather than independent, sets of genes Cell 97 1999 727 741
92. A. Schulze, K. Lehmann, H.B.J. Jefferies, M. McMahon, and J. Downward Analysis of the transcriptional program induced by Raf in epithelial cells Genes Dev 15 2001 981 994
93. J. Svaren, T. Ehrig, S.A. Abdulkadir, M.U. Ehrengruber, M.A. Watson, and J. Milbrandt EGR1 target genes in prostate carcinoma cells identified by microarray analysis J Biol Chem 275 2000 38531 385240
94. V.D. Leaner, I. Kinoshita, and M.J. Birrer AP-1 complexes containing cJun and JunB cause cellular transformation of Rat1a fibroblasts and share transcriptional targets Oncogene 22 2003 5616 5629
95. E. Huang, S. Ishida, and J. Pittman Gene expression phenotypic models that predict the activity of oncogenic pathways Nat Gen 34 2003 226 230
96. C.J. Roberts, B. Nelson, and M.J. Marton Signaling and circuitry of multiple MAPK pathways revealed by a matrix of global gene expression profiles Science 287 2000 873 880
97. R.J. Cho, M.J. Campbell, and E.A. Winzeler A genome-wide transcriptional analysis of the mitotic cell cycle Mol Cell 2 1998 65 73
98. N.S. Gray, L. Wodicka, and A.-M.W.H. Thunnissen Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors Science 281 1998 533 538
99. M.J. Marton, J.L. DeRisi, and H.A. Bennett Drug target validation and identification of secondary drug target effects using DNA microarrays Nat Med 4 1998 1293 1301
100. T.R. Hughes, M.J. Marton, and A.R. Jones Functional discovery via a compendium of expression profiles Cell 102 2000 109 126
101. E.P. Black, E. Huang, and H. Dressman Distinct gene expression phenotypes of cells lacking Rb and Rb family members Cancer Res 63 2003 3716 3723
102. H.J. Andreyev, A.R. Norman, D. Cunningham, J.R. Oates, and P.A. Clarke Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study J Natl Cancer Inst 90 1998 675 684
103. P.J. Ross, M. George, and D. Cunningham Inhibition of Kirsten-ras expression in human colorectal cancer using rationally selected Kirsten-ras antisense oligonucleotides Mol Cancer Ther 1 2001 29 41
104. R.S. Kamath, A.G. Fraser, and Y. Dong Systematic functional analysis of the Caenorhabditis elegans genome using RNAi Nature 421 2003 231 237
105. J.T. Chi, H.Y. Chang, N.N. Wang, D.S. Chang, N. Dunphy, and P.O. Brown Genomewide view of gene silencing by small interfering RNAs Proc Natl Acad Sci USA 100 2003 6343 6346
106. D. Semizarov, L. Frost, A. Sarthy, P. Kroeger, D.N. Halbert, and S.W. Fesik Specificity of short interfering RNA determined through gene expression signatures Proc Natl Acad Sci USA 100 2003 6347 6352
107. K. Berns, E.M. Hijmans, and J. Mullenders A large-scale RNAi screen in human cells identifies new components of the p53 pathway Nature 428 2004 431 437
108. S. Varambally, S.M. Dhanasekaran, and M. Zhou The polycomb group protein EZH2 is involved in progression of prostate cancer Nature 419 2002 624 629
109. D.T. Ross, U. Scherf, and M.B. Eisen Systematic variation in gene expression patterns in human cancer cell lines Nat Gen 24 2000 227 235
110. U. Scherf, D.T. Ross, and M. Waltham A gene expression database for the molecular pharmacology of cancer Nat Gen 24 2000 236 244
111. A. Wallqvist, A.A. Rabow, R.H. Shoemaker, E.A. Sausville, and D.G. Covell Establishing connections between microarray expression data and chemotherapeutic cancer pharmacology Mol Cancer Ther 1 2002 311 320
112. J.E. Staunton, D.K. Slonim, and H.A. Coller Chemosensitivity prediction by transcriptional profiling Proc Natl Acad Sci USA 98 2001 10787 10792
113. S. Dan, T. Tsunoda, and O. Kitahara An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines Cancer Res 62 2002 1139 1147
114. G. Musumarra, D.F. Condorelli, S. Scire, and A.S. Costa Shortcuts in genome-scale cancer pharmacology research from multivariate analysis of the national cancer institute gene expression database Biochem Pharmacol 62 2001 547 553
115. P.E. Blower, C. Yang, and M.A. Fligner Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data Pharmacogenom J 2 2002 259 271
116. A.J. Butte, P. Tamayo, D. Slonim, T.R. Golub, and I.S. Kohane Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks Proc Natl Acad Sci USA 97 2002 12182 12186
117. M. Moriyama, Y. Hoshida, and M. Otsuka Relevance network between chemosensitivity and transcriptome in human hepatoma cells Mol Cancer Ther 2 2003 199 205
118. H. Zembutsu, Y. Ohnsihi, and Y. Furukawa Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs Cancer Res 62 2002 518 527
119. W.C. Reinhold, H. Kouros-Mehr, and K.W. Kohn Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping Cancer Res 63 2003 1000 1011
120. G.S. Watts, B.W. Futscher, R. Isett, M. Gleason-Guzman, M.W. Kunkel, and S.E. Salmon cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways J Pharmacol Exp Ther 299 2001 434 441
121. R. Wittig, M. Nessling, and R.D. Will Candidate genes for cross-resistance against DNA-damaging drugs Cancer Res 62 2002 6698 6705
122. V.V. Levenson, I.A. Davidovich, and I.B. Roninson Pleiotropic resistance to DNA-interactive drugs is associated with increased expression of genes involved in DNA replication, repair and stress response Cancer Res 60 2000 5027 5030
123. W. Wang, S. Marsh, J. Cassidy, and H.L. McLeod Pharmacogenomic dissection of resistance to thymidylate synthetase inhibitors Cancer Res 61 2001 5505 5510
124. D.E. Lamendola, Z. Duan, R.Z. Yusef, and M.V. Seiden Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line Cancer Res 63 2003 2200 2205
125. P. Workman Challenges of PK/PD measurements in modern drug development Eur J Cancer 38 2003 2189 2193
126. Y. Zhou, F.G. Gwadry, and W.C. Reinhold Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects Cancer Res 62 2002 1688 1695
127. S.A. Amundson, M. Bittner, Y. Chen, J. Trent, P. Meltzer, and A.J. Fornace Fluorescent cDNA microarray hybridisation reveals complexity and heterogeneity of cellular genotoxic stress responses Oncogene 18 1999 3666 3672
128. S.S. Daoud, P.J. Munson, and W. Reinhold Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study Cancer Res 63 2003 2782 2793
129. K. Kudoh, M. Ramanna, and R. Ravatn Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray Cancer Res 60 2000 4161 4166
130. B.-D. Chang, M.E. Swift, M. Shen, J. Fang, E.V. Broude, and I.B. Roninson Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent Proc Natl Acad Sci USA 99 2002 389 394
131. Q. Yu, M. He, N.H. Lee, and E.T. Liu Identification of Myc-mediated death response pathways by microarray analysis J Biol Chem 277 2002 13059 13066
132. D. Arango, G.A. Corner, S. Wadler, P.J. Catalano, and L.H. Augenlicht c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo Cancer Res 61 2001 4910 4915
133. D.J. Taxman, J.P. Mackinaw, C. Clements, D.T. Bergstralh, and J.P.-Y. Ting Transcriptional profiling of targets for combination therapy of lung carcinoma with paclitaxel and Mitogen-activated protein/extracellular signal-related kinase kinase inhibitor Cancer Res 63 2003 5095 5104
134. P.J. Maxwell, D.B. Longley, and T. Latif Identfication of 5-fluorouracil-inducible target genes using cDNA microarray profiling Cancer Res 63 2003 4602 4606
135. D. Friedman, Z. Hu, E.A. Kolb, B. Gorfajn, and K.W. Scotto Ecteinascidin-743 inhibits activated but not constitutive transcription Cancer Res 62 2002 3377 3381
136. F.G. Bottone jr, J.M. Martinez, J.B. Collins, C.A. Afshari, and T.E. Eling Gene modulation by the cyclooxgenase inhibitor, sulindac sulphide, in human colorectal carcinoma cells J Biol Chem 278 2003 25790 25801
137. S. Easdale, P.A. Clarke, and J. Titley Genes expression and cell cycle analysis of HT29 human colon cancer cells, exposed to celecoxib, indomethacin, sulindac sulphide and sulindac sulphone Proc Am Assoc Cancer Res 44 2003 914
138. I. Vivanco, and C.L. Sawyers The phosphatidylinositol 3-kinase AKT pathway in human cancer Nat Rev Cancer 2 2002 489 501
139. R. Kristeleit, L. Stimson, P. Workman, and W. Aherne Histone modification enzymes: novel targets for cancer drugs Expert Opin Emerg Drugs 9 2004 135 154
140. K.B. Glaser, M.J. Staver, J.F. Waring, J. Stender, R.G. Ulrich, and S.K. Davidsen Gene expression profiling of multiple histone deacetylase (hdac) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines Mol Cancer Ther 2 2003 151 163
141. G. Liang, F.A. Gonzales, P.A. Jones, T.F. Orntoft, and T. Thykjaer Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor Cancer Res 62 2002 961 966
142. D.V. Vanaja, J.C. Cheville, S.J. Iturria, and C.Y.F. Young Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression Cancer Res 63 2003 3877 3882
143. L.T. Lam, O.K. Pickeral, and A.C. Peng Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol Genome Biol 2 2001 RESEARCH 0041
144. S.R. Whittaker, R. te Poele, and M.I. Walton Gene expression profiling of the cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) Proc Am Assoc Cancer Res 44 2003 797
145. P.A. Clarke, I. Hostein, and U. Banerji Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone Oncogene 19 2000 4125 4133
146. W. Aherne, A. Maloney, and S. Sharp Discovery of a novel synthetic inhibitor of the Hsp90 molecular chaperone Proc Am Assoc Cancer Res 44 2003 915
147. E.C. Gunther, D.J. Stone, R.W. Gerwien, P. Bento, and M.P. Heyes Prediction of clinical drug efficacy by classification of drug-induced genomic expression profiles in vitro Proc Natl Acad Sci USA 100 2003 9608 9613
148. T. Owa, A. Yokoi, K. Yamazaki, K. Yoshimatsu, T. Yamori, and T. Nagasu Array-based structure and gene expression relationship study of antitumor sulfonamides including N-[2-[(4-hydroxyphenoyl)amino]-3-pyridinyl]-4- methoxybenzenesulfonamide and N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide J Med Chem 45 2002 4913 4922
149. A. Yokoi, J. Kuromitsu, and T. Kawai Profiling novel sulfonamide antitumour agents with cell-based phenotypic screens and array-based gene expression analysis Mol Cancer Ther 1 2002 275 286
150. A. Monks, E. Harris, C. Hose, J. Connelly, and E.A. Sausville Genotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modifications underlying toxicity of the anticancer drug 2-(4-amino-3- methylphenyl)-5-fluorobenzothiazole Mol Pharmacol 63 2003 766 772
151. P.H. Johnson, R.P. Walker, and S.W. Jones Multiplex gene expression analysis for high-throughput drug discovery: screening and analysis of compounds affecting genes overexpressed in cancer cells Mol Cancer Ther 1 2002 1293 1304
152. D.K. Bol, D.R. Soppert, and A. Glodek The changing landscape of drug discovery screening Curr Drug Discovery 3 2003 17 21
153. L. Assersohn, L. Gangi, and Y. Zhao The feasibility of using fine needle aspiration from primary breast cancer for cDNA microarray analysis Clin Cancer Res 8 2002 794 801
154. T.A. Buchholz, D.N. Stivers, and J. Stec Global gene expression changes during neoadjuvant chemotherapy for human breast cancer Cancer J 8 2002 461 468
155. L. Pusztai, M. Ayers, and J. Stec Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors Clin Cancer Res 9 2003 2406 2415
156. J.C. Chang, E.C. Wooten, and A. Tsimeizon Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer Lancet 362 2003 362 369
157. C. Sotiriou, T.J. Powles, and M. Dowsett Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer Breast Cancer Res 4 2002 R3
158. W.K. Hofmann, S. de Vos, and D. Elashoff Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study Lancet 359 2002 481 486
159. M.H. Cheok, W. Yang, C.-H. Pui, J.R. Downing, C. Cheng, and C.W. Naeve Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells Nat Genet 34 2003 85 90
160. R.L. Stears, T. Martinsky, and M. Schena Trends in microarray analysis Nat Med 9 2003 140 145